Pharmafile Logo

Omthera Pharmaceuticals

- PMLiVE

Lynparza set for further expansion with EU approval in breast cancer

Companies have prostate cancer and pancreatic cancer in their sights

- PMLiVE

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Part of R&D and commercial collaboration with MSD

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

AstraZeneca AZ

AZ to address Imfinzi setback, but sees potential with Tagrisso

Pharma giant to deliver oncology pipeline update at AACR

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

Cancer drugs and China sustain AZ’s return to growth

Tagrisso set to become biggest seller

- PMLiVE

AZ’s Sean Bohen to exit after business overhaul; report

Recent departures raises concern among analysts

- PMLiVE

AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

Underlines importance of cancer drugs to company's future growth

- PMLiVE

AstraZeneca wins NICE backing for asthma injection

NICE hails 'competitive pharma market'

- PMLiVE

First-line ovarian approval cements AZ’s Lynparza lead

Also new data on recently approved kidney disease drug

- PMLiVE

China first market to approve AZ’s kidney drug roxadustat

A milestone for China and AZ and partners FibroGen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links